English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Tissue concentrations of ofloxacin (OFLX) and pronase were determined in 58 tonsils and 43 maxillary sinus mucosal biopsies collected surgically after a single oral dose of 200mg of OFLX with or without a daily dose of 54, 000 units of pronase given for the previous 4 days. In tonsils the tissue concentration of OFLX 90 minutes after administration was 2.37μg/g in the OFLX group and 3.72μg/g in the combined group. In maxillary sinus mucosa the tissue OFLX concentration 90 minutes after administration was 1.29μg/g in the OFLX group and 1.79μg/g in the combined group. In both specimens penetration in the combined group was higher than in the OFLX group.The clinical effectiveness, safety and utility were evaluated in 39 patients with paranasal sinusitis who were given OFLX in a daily dose of 600mg for 14 to 28 days with or without pronase in a daily dose of 54, 000 units. In the combined group the clinical efficacy, defined as percentage of patients with exellent or good responses, was 42.9% in those with chronic sinusitis and 83.3% in those with acute exacerbation of chronic sinusitis. On the other hand, in the OFLX group the efficacy was 40% and 50%, respectively. No clinical side effects were observed in the combined group.The results indicate that OFLX with pronase is useful in the treatment of chronic sinusitis and tonsillitis.

Clinical Study of Combined Use of Ofloxacin and Pronase.